# A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

> **NCT02677896** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 1150 (actual)

## Conditions studied

- Metastatic Hormone Sensitive Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02677896
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-09
- **Primary completion:** 2018-10-14
- **Final completion:** 2024-07-31
- **Target enrollment:** 1150 (ACTUAL)
- **Last updated:** 2025-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02677896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02677896, "A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02677896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*